Last reviewed 2026-05-22 · How we verify

Rnalozine

University of New Mexico · Phase 1 active Small molecule ✓ Verified May 2026

Rnalozine is a Small molecule drug developed by University of New Mexico. It is currently in Phase 1 development. Also known as: Ranexa, Ranalozine.

Ranolazine is a medication studied for its effects on coronary microcirculation, coronary artery disease, myocardial disease, and ischemia. It is being investigated in a clinical trial, NCT01815957, to evaluate its impact on coronary microcirculatory resistance.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Rnalozine
Also known as	Ranexa, Ranalozine
Sponsor	University of New Mexico
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Impact of Ranolazine on Coronary Microcirculatory Resistance (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rnalozine CI brief — competitive landscape report
Rnalozine updates RSS · CI watch RSS
University of New Mexico portfolio CI

Frequently asked questions about Rnalozine

What is Rnalozine?

Rnalozine is a Small molecule drug developed by University of New Mexico.

Who makes Rnalozine?

Rnalozine is developed by University of New Mexico (see full University of New Mexico pipeline at /company/university-of-new-mexico).

Is Rnalozine also known as anything else?

Rnalozine is also known as Ranexa, Ranalozine.

What development phase is Rnalozine in?

Rnalozine is in Phase 1.

Manufacturer: University of New Mexico — full pipeline
Therapeutic area: All drugs in Other
Also known as: Ranexa, Ranalozine

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing